This invention can be used to treat or prevent any disease or disorder associated with aberrant insulin or insulin-like growth factor 1 signaling, including but not limited to, diabetes, obesity, cancer, hyperglycemia, hypoglycemia, cardiovascular disease, syndrome X, neurodegeneration and Alzheimer’s disease, appetite control, osteoporosis, decreased muscle mass, psoriasis, gigantism, and immune modulation disorders.
Improper insulin-regulation of blood glucose levels leads to diabetes and obesity. Likewise, insulin-like growth factor 1 (IGF-1), a single-chain protein that stimulates cell differentiation and proliferation and has a possible role in metabolic pathways, has been implicated in a number of cancers. Insulin and IGF-1 are similar in size, sequence and structure and have low affinity to each other’s receptors: insulin receptor (IR) and IGF-1 receptor (IGF-1R) respectively. This technology includes IR and IGF-1R agonists and antagonists to control the insulin and IGF-1 signaling pathways which are responsible for glucose levels, lipid metabolism, DNA and RNA synthesis, and cellular proliferation.
This technology includes the discovery of IR and IGF-1R agonists and antagonists. Insulin binding receptor activators such as s-CPG15, CPG15-2, and s-CPG15-2 can act as agonists (either directly or indirectly) to the insulin-binding receptors by activation of signaling pathways or by recruiting downstream signaling proteins. Furthermore, inhibitors of s-CPG15 or CPG15-2 (including inhibitors of s-CPG15-2), such as dominant negative forms of CPG15 or CPG15-2, can block the function of insulin and IGF-1 but not that of other growth factors, such as BDNF and NT-3. Therefore, s-CPG15 or s-CPG15-2 compounds and inhibitors can be used to treat or prevent any number of disorders associated with aberrant insulin or IGF-1 signaling including the regulation of blood glucose levels.
Allows treatment for a wide-variety of disorders caused by improper insulin and IGF-1 signaling
Antagonists do not block other growth factors